One of the programs affected by this announcement is the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). This program has invested more than US$100 billion in the global HIV/AIDS ...

AIDS arrived as American politics took a sharp conservative turn with the election of President Ronald Reagan. When in 1985 it became possible to test for HIV, the virus that causes AIDS, the prospect ...

United States funding cuts to HIV/AIDS programmes in many African countries could lead to hundreds of thousands of deaths on the continent, health experts and aid organisations have warned.

After a lifetime on the frontiers of the fight against HIV, Linda-Gail Bekker could finally see the end of the epidemic in sight. For decades, HIV experts had dreamed of an elusive vaccine to ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according to a new study by a team of US and Malawian researchers. Their ...

The 2003 inception of the US President’s Emergency Plan for AIDS Relief, or PEPFAR, provided new hope for children living with HIV around the continent, including the orphans at Nyumbani.

what the Joint United Nations Programme on HIV and AIDS calls a clear inability to transmit the virus sexually) only remains that way if they’re taking their medication properly, which means ...

I was volunteering at George House Trust – a charity which offers support to people living with HIV – cataloguing ... book for people who died of AIDS. As I read those words, surrounded ...

NBC News' Jay Valle reports from a nonprofit clinic in Florida that provides free HIV care to Latinos most vulnerable to the disease. IE 11 is not supported. For an optimal experience visit our ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as shareholders, announced new data from two ...

Please use one of the following formats to cite this article in your essay, paper or report: APA Sino Biological Inc.. (2025, March 12). Gilead’s capsid revolution meets our capsid solutions ...

Gilead (GILD) Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of lenacapavir, the company’s injectable HIV-1 capsid inhibitor ...